FUTURE platform trial

Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III "PREVENT" Trial of the AIO /CAOGI /ACO

Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors

A Phase III, Randomized, open-label study evaluating the efficacy and safety of Divarasib and Pembrolizumab versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in patients with previously untreated, KRAS G12C-mutated, advanced or metastatic non-squamous non−small cell lung cancer

A randomized phase II study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor based endocrine therapy as first line therapy of HR-positive and HER2-low/ultralow advanced breast cancer patients classified as non-luminal subtype according to gene expression profiling

Prospektives, akademisches, translationales Forschungs-Netzwerk zur Optimierung der onkologischen Gesundheitsversorgung Qualität in der adjuvanten und der fortgeschrittenen/metastasierten Situation: Gesundheitsforschung, Pharmakogenomik, Biomarker, Gesundheitsökonomie PRAEGNANT Brustkrebs: Fortgeschritten/ Metastasierend

 A Phase 3, Randomized, Open Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants with relapesd, refractory Multiple Myeloma (KT-US-679-0788, iMMagine-3)